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People eating different balances of omega-3 and omega-6 nutrients develop predictably different
proportions of competing highly unsaturated fatty acids (HUFA) in their tissue lipids. While epidemio-
logical studies have associated wide differences in HUFA balance with disease severity, some clinical
studies that did not examine wide differences failed to conﬁrm the association. We examined the degree
to which the relative amount of arachidonic acid, the major precursor of omega-6 eicosanoids, differs
among people who have widely different dietary intakes of omega-3 and omega-6 nutrients. Gas
chromatographic analyses of human blood samples describe the balance among n-3 and n-6 HUFA for
different individuals. The proportion of the omega-6 arachidonic acid, fromwhich potent eicosanoids are
formed, is not constant. It ranges from 30% to 70% of HUFA while the competing n-3 HUFA range from
60% to 10% of HUFA. Signiﬁcant differences in clinical outcomes between control and intervention groups
have been seen when using dietary interventions that shift the balance of n-3 and n-6 nutrients far
enough to create a biologically signiﬁcant difference in the HUFA balance.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Clinical decisions about the efﬁcacy of omega-3 nutrients in
moderating risks for health disorders related to omega-6 mediators
may be improved by viewing the accumulated tissue levels in the
context of the omega-3 acids competing with the omega-6 acids that
form potent eicosanoid mediators. Many aspects of fatty acid meta-
bolism involve an individual acid acting in the presence of competing
closely-related acids. Reports of acyl chain turnover and phospholipid
retailoring began in 1958 and led to a series of papers on selective
placement of competing acyl chains by lysophospholipid acyltrans-
ferases and how beneﬁcial effects come from balancing omega-6 (n-6)
fatty acids with omega-3 (n-3) fatty acids [1]. Erythrocytes have a
simple system for lecithin synthesis [2] in which unesteriﬁed fatty
acids and lysophosphatidyl choline from plasma combine to form
phosphatidylcholines that are retained in themembrane or released in
facile exchanges with circulating lipoproteins. Relative abundances of
competing substrate acids combine with enzymatic selectivities to
predict closely the composition of fatty acids accumulated at the 2-
position of phospholipids in human, rat and cow erythrocytes [2].
When dose-response studies with high afﬁnity acyl-CoA substrates
required unmanageably low concentrations, competitive effectiveness
of acyl-CoA substrates was measured against arachidonoyl-CoA [3].
Competitive studies help interpret the relative ability of various
polyunsaturated acyl-CoAs to accumulate in phospholipids from the
mixture of competing substrates usually present in cells [4]. Many
different lysophospholipid acyltransferases are now recognized [5,6],
and the set of lysophospholipid acyltransferases in liver microsomes
has an overall selective afﬁnity for more highly unsaturated substrates
relative to less unsaturated ones. However, that set does not dis-
criminate appreciably between the omega-6 (n-6) or omega-3 (n-3)
structure of HUFA that eventually serve as precursors of bioactive
prostaglandins and leukotrienes. Docosahexaenoyl-CoA competed
effectively with arachidonoyl-CoA, but it was transferred slowly and
inhibited the overall rate of transferase action [3].
Linoleic and linolenic acids have similar competing hyperbolic
dose-response actions in the elongation and desaturation steps that
form the HUFA which accumulate in rat liver lipids [7,8]. This non-
linear metabolic relationship was conﬁrmed quantitatively with an
empirical predictive equation that describes how the balance of n-3
and n-6 nutrients expressed as a percent of daily food energy (en%)
leads to the accumulated proportions of n-3 and n-6 HUFA [9]. The
empirical competitive hyperbolic equation also ﬁt data from studies
with humans [10], and it was extended to ﬁt studies with added
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dietary n-3 HUFA for humans, rats and mice [10]. More quantitative
dietary data from humans led to slight revisions of three constants to
better ﬁt all of the combined results [11]. A subsequent literature
search and analysis [12] showed that the revised empirical equation
estimated well the observed balance of tissue n-3 and n-6 HUFA that
developed from known daily intakes of n-3 and n-6 nutrients for
nearly 4000 people in 92 subject groups in 34 different studies from
11 different countries.
When developing the 1992 quantitative empirical equation relat-
ing dietary essential fatty acid intakes to the balance of accumulated
tissue n-3 and n-6 HUFA [10], the authors noted that the proportion of
n-6 acids in the HUFA of different populations was related to the
incidence of heart attacks. If atherogenesis and thrombosis were
mediated by n-6 eicosanoids, their severity might depend in part on
the relative amounts of n-6 arachidonate and n-3 HUFA that competi-
tively interact with cytosolic phospholipase A2 (cPLA2) as it initiates
eicosanoid formation.
The evidence cited above suggests that the balance of competing
n-3 and n-6 nutrients in foods eaten by each individual predictably
affects the balance of n-3 and n-6 HUFA. Nevertheless, some research-
ers have suggested that arachidonic acid levels are constant in blood
lipids and poorly related to health conditions. To see the degree to
which the proportions of arachidonate and competing individual
HUFA actually differ among people who have widely different dietary
intakes of n-3 and n-6 nutrients, we examined analytical results from
over a thousand Americans eating diverse food combinations.
2. Methods
Gas chromatographic data on HUFA balance in ﬁnger-tip blood-
spot samples were obtained from archived historic de-identiﬁed
records from 1015 Americans during the past two years. More records
were not used after 500 random samples added to the ﬁrst 500 did
not alter the pattern of results. Each anonymous electronic record
describes the wt% amount of 35 different fatty acids, including seven
major n-3 and n-6 20- to 22-carbon highly unsaturated fatty acids
(HUFA). The samples of blood had been collected on paper [13], and
the gas chromatographic values were expressed as proportions of
competing n-3 and n-6 in the total HUFA as proposed at the 2004
ISSFAL Congress in Brighton, UK, [14]. The %n-6 in HUFA relates closely
to the average daily balance of n-3 and n-6 nutrients ingested by
individuals [10]. To avoid introducing any bias, the analytical values
were not adjusted or modiﬁed by any further mathematical
transformations.
3. Results
Fig. 1 shows the relative proportions of selected HUFA among the
total HUFA in each blood sample. The mean and median values of %n-
6 in HUFA (66% and 68%, respectively) are less than the 76–80% often
reported for Americans [15]. The wide range of %n-6 in HUFA in this
study reﬂects inclusion of many samples from individuals interested in
eating more omega-3 nutrients in their daily diets. The proportion of
n-3 and n-6 acids in blood HUFA has been reported to be a useful
predictor of competing n-3 and n-6 biological roles [14,16]. Once
formed, the n-3 and n-6 HUFA move in and out of diverse lipid pools
with similar turnovers. Metherel et al [17] showed that the relative
proportion of n-6 in HUFA was near 78% for samples of plasma,
erythrocytes, whole blood and ﬁnger-tip blood spot samples even
when the n-6 HUFA content differed from 7.7 to 17 wt% (and n-3
HUFA from 2 to 5 wt%).
Expressing HUFA abundance in the context of other competing
HUFA differs from the technical analytical laboratory report of
fatty acid composition which describes relative amounts of fatty
acids as a percent by weight (wt%) of all acids analyzed in a
sample. The wt% value has a simple “housekeeping” rationale, but
it has no clear metabolic or biological signiﬁcance. One strength of
the HUFA-oriented context for using the %n-6 in HUFA is that it
avoids including noise from saturated, monoenoic and dienoic
acids which have metabolic selectivities different than the HUFA
that interact strongly with cPLA2.
Fig. 2A shows that wt% values for linoleic acid (LA), the major
precursor of tissue arachidonate, varied from 10.9% to 38.3% with a
mean of 25.9% and a median of 25.9%. The wt% values for linoleate
varied little in relationship to the diet-related biomarker, %n-6 in
HUFA. The means for linoleic quintiles ranged from 21% to 31%
(Table 1A). Paradoxically, the quintiles of progressively higher wt%
linoleic acid in this study had progressively lower wt% levels of its
major HUFA metabolite, arachidonate (AA). It is likely that none of the
samples studied were from people eating linoleate at levels in the
linear dose-response range of 0 to 1 en% for dietary linoleic acid
conversion to tissue HUFA [7,10]. The quintiles of wt% LA also had no
signiﬁcant association with other variables (%AA in HUFA, %n-3 in
HUFA and %n-6 in HUFA) which are related to eicosanoid biosynthesis.
Arachidonate (AA) levels expressed as wt% of all acids in the sample
had values that varied from 3.9% to 22.3% (mean¼10.0%) and was
higher when the %n-6 in HUFA was higher (Fig. 2), although the wt%
values scarcely escaped the noise envelope for people maintaining
typical American levels of 70% to 80%n-6 in HUFA. More importantly,
the relative proportion of arachidonate within the HUFA differs from
39% to 61%, and it clearly relates to the quintiles of the diet-related
biomarker, %n-6 in HUFA (Table 1B). The diet-related biomarker
ranged from 25.3% to 93.9% (mean¼66.1; median¼68.2), and the
quintiles had mean values of 48, 61, 68, 73 and 80.
Fig. 2B shows that wt% values for the most abundant dietary
precursor of tissue n-3 HUFA, alpha-linolenic acid (ALA), had a very
low with a mean value of 0.7%, and the values varied little in
relationship to the diet-related biomarker, %n-6 in HUFA. For most
people studied, the wt% of DHA was below 5% while the %DHA in
HUFA ranged from 7% to 30%. A sharper focus on the competing HUFA
derivatives is further illustrated in Fig. 3 where the relative abundance
of arachidonate in HUFA is compared with the sum of competing n-3
HUFA in the blood sample. If the balance between competing n-3
HUFA and arachidonate inﬂuences the substrates made available for
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Fig. 1. Balance among competing n-3 and n-6 HUFA. Analysis of the proportions of
individual HUFA among total HUFA in 1015 whole blood samples show lower
proportions of 20:4n-6 (AA) when proportions of 20:5n-3 (EPA), 22:5n-3 (DPA) and
22:6n-3 (DHA) are higher. The proportions of 20:3n-6, 22:4n-6, and 22:5n-6 were
all less than 10% of HUFA and are not shown. The dotted lines represent
approximate HUFA balances for people in the indicated regional groups with
different traditional food habits that cause different %n-6 in HUFA (34).
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eicosanoid formation, it likely has important biological consequences
that will affect decision making in medical practice, policy, education,
and research.
4. Discussion
The cPLA2 hydrolase action that initiates eicosanoid-mediated
responses favors highly unsaturated substrates (20:4418:3418:24
18:1416:0), but it does not discriminate appreciably between the n-6
and n-3 HUFA that serve as precursors of eicosanoids [18]. The
indiscriminate action allows the diet-determined HUFA balance in
tissues to be reﬂected in the released substrates. The cPLA2 resembles
the acyltransferase in being slowed by competing DHA substrates [19],
perhaps due to steric hindrance from the carbon 4 double bond being
near the ester bond. In this way, the presence of DHA may slow the
release of both EPA and AA. Overall, the cPLA2 preference for HUFA
combines with the relative abundance of arachidonate within the
HUFA available (Fig. 1) to provide diet-dependent competing n-3 and
n-6-mediators that have different biological outcomes.
A comprehensive study of the relative intensity of eicosanoid
formation and action [20] showed that many steps after phospho-
lipase release are less vigorous for n-3 than competing n-6
analogs. For example, prostaglandin synthase forms prostaglan-
dins [20] and leukotriene C synthase forms cysteinyl leukotrienes
[21] with less intensity when using the omega-3 rather than
omega-6 substrate. Blood platelet aggregation, which mediates
thrombotic heart attacks, was less when the HUFA balance shifted
toward less n-6 HUFA [22]. Also, the chemotaxis that mediates
many immune-inﬂammatory disorders may be 50-fold less with
the omega-3 LTB5 than for the omega-6 LTB4 [23]. These examples
illustrate important processes in which the context of balance
among competing tissue HUFA has a vital role in interpreting the
subsequent clinical outcomes.
Common health problems made worse by excessive omega-6
eicosanoid actions include atherosclerosis, arthritis, asthma, bone loss,
cancer growth, heart attacks, length of hospital stays, depression,
suicide, classroom disruptions, oppositional behavior and unproduc-
tive workplace behaviors [24]. Importantly, the proportion of HUFA
that is arachidonate (AA), from which potent n-6 eicosanoids are
Weight %  or  % in HUFA?
0
10
20
30
40
50
60
70
25 35 45 55 65 75 85
Proportion of n-6 in HUFA
Pe
rc
en
ta
ge
  v
al
ue
%AA in HUFA
wt% AA
wt% LA
Weight % or % in HUFA? 
0
5
10
15
20
25
30
35 45 55 65 75 85
Proportion of n-6 in HUFA
Pe
rc
en
ta
ge
  v
al
ue
wt%ALA
DHA%in HUFA
wt%EPA
wt%DHA
Fig. 2. Comparing two modes of describing abundances. 2A.The wt% of linoleate (LA) and arachidonate (AA) are less associated with the proportion of n-6 in HUFA than is
the percent of arachidonate in HUFA. 2B. The wt% of alpha-linolenate (ALA), EPA and DHA are less clearly associated with the proportion of n-6 in HUFA than is the percent of
DHA in HUFA.
Table 1
Comparison of biomarkers in quintiles of wt% of linoleic acid and quintiles of %n-6 in HUFA.
A. Quintiles of wt% of linoleic acid in total acids
Wt%18:2n-6 Q1 Q2 Q3 Q4 Q5
10.9 to 38.3 21.2 (2.1) 24.2 (0.5) 25.9 (0.5) 27.6 (0.6) 30.8 (1.6)
Wt%20:4n-6 10.0 (2.1) 10.2 (2.1) 10.0 (1.9) 9.9 (1.7) 9.7 (1.6)
%AAinHUFA 50.3 (10.3) 51.6 (9.3) 51.9 (8.0) 52.4 (7.0) 52.8 (7.4)
%n-3inHUFA 35.2 (14.3) 34.1 (12.3) 33.5 (10.5) 33.2 (9.9) 33.3 (10.1)
%n-6inHUFA 64.8 (14.3) 65.9 (12.3) 66.5 (10.5) 66.8 (9.9) 66.7 (10.1)
B. Quintiles of percent of n-6 HUFA in total HUFA
%n-6 in HUFA Q1 Q2 Q3 Q4 Q5
25.3 to 93.9 48.2 (7.1) 60.9 (2.3) 68.1 (1.6) 73.4 (1.6) 80.1(2.9)
Wt%18:2n-6 25.2 (3.8) 26.5 (3.3) 26.4 (3.6) 26.1 (3.1) 25.5 (3.3)
Wt%20:4n-6 8.1 (1.5) 9.5 (1.4) 10.3 (1.4) 10.8 (1.4) 11.2 (2.0)
%AAinHUFA 38.8 (5.7) 48.8 (3.3) 53.7 (2.6) 57.1 (2.9) 60.6 (4.2)
%n-3inHUFA 51.8 (7.1) 39.1 (2.3) 31.9 (1.6) 26.6 (1.6) 19.9 (2.9)
Each quintile (n¼203) has values for the biomarkers as means with standard deviations in
parentheses. The range of 18:2n-6 values in A is 10.9 to 38.3 wt%. The range of values in B for %
n-6 in HUFA is 25.3% to 93.9%.
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formed, is not constant. Fig. 1 shows that AA can range from 30% to
70% of HUFA while the competing EPA proportion ranges from 25% to
5% and the DHA proportion from 30% to 10% of HUFA. Long-
recognized differences in heart attack mortality rates for people in
Greenland, Japan and Mediterranean countries, all of which were
lower than that for Americans and Northern Europeans [25] were
closely associated (r2¼0.99) with observed proportions of n-6 in
HUFA for these groups [26]. Thus, the balance of n-3 and n-6 acids in
blood HUFA is a useful health risk assessment biomarker in addition to
being a useful measure of daily average intakes of the competing n-3
and n-6 nutrients in foods. The following examples about disease risk
compare reports that either did or did not examine a wide rangfe of
HUFA balance values. They illustrate how a transparent display of the
measured HUFA balance gives a clear context for developing con-
structive clinical interpretations of the efﬁcacy of dietary omega-3
interventions for lowering excessive n-6 eicosanoid actions in several
health conditions.
A paradox occurs in the apparent dissonance between a cross-
national association of depression with low intakes of n-3 HUFA
[27] that contrasts with a large longitudinal study of American
women which found no statistically signiﬁcant association [28].
However, estimates of the likely HUFA balance in the different
groups (using the empirical relationship described in the intro-
duction) suggest the estimated HUFA balance ranged from 30% to
80%n-6 in HUFA (Fig. 3, Ref. [27]) for the cross-national report, and
it ranged from only 69% to 73%n-6 in HUFA for the quintiles of
54,632 women in the longitudinal study (Fig. 2, Ref. [28]). The
latter report used quintiles of ALA intake to deﬁne statistically
signiﬁcant numerically different subsets of the group, but those
subsets may not deﬁne biologically signiﬁcant differences (for
example, see ALA wt% values in Fig. 2B). It seems likely that a
clinical study with a wider range of the biologically signiﬁcant
HUFA balance might have quintiles with signiﬁcant differences in
depression.
Another paradoxical example of an apparent dissonance
involves the widely different prostate cancer mortality rates in
ﬁve different countries [29] which is associated with estimates of
likely HUFA balance that ranged from 35%n-6 in HUFA for “tradi-
tional” Japanese, 50%n-6 in HUFA for “modern” Japanese” [11]
compared to 60%n-6 in HUFA for Italy and about 70–80%n-6 in
HUFA for UK and USA [15]. This association of HUFA proportions
with prostate cancer deaths contrasts with interpretations from
two recent nested case–control comparisons: controls had 77%n-6
in HUFA compared to 77% in low-grade cases and 76% in high-
grade cases in one study [30], and a second study had 72%n-6 in
HUFA in controls compared to 71% in low-grade and high-grade
cases [31]. In these two studies with a very narrow range of HUFA
balance, the authors interpreted data by grouping individuals by
quartiles of the n-3 HUFA weight percent in the total plasma
phospholipid fatty acids. This parameter has a different biological
signiﬁcance than the balance of competing n-3 or n-6 in HUFA
(Fig. 1), and it did not have the wide biologically signiﬁcant range
of %n-6 in HUFA seen in the cross-national study. Viewing a wider
biological range of HUFA balance and including the context of
competing n-3 and n-6 HUFA will likely give more valid inter-
pretations of fatal prostate tumorigenesis.
A third example of apparent contradiction occurred with rando-
mized controlled clinical trials of patients with chronic pain. A 2001
study [32] reported that increased intakes of n-3 HUFA failed to give a
signiﬁcant difference in the number of pain attacks in the last 4 weeks
of the comparative treatment period. In contrast, a 2013 report [33]
used concepts mentioned in the introduction to design sufﬁcient
lowering of the competing n-6 nutrients for three months to lower the
%n-6 in HUFA of erythrocytes from 78% to 74%. This protocol led to a
small, statistically signiﬁcant lower self-administration of acute med-
ications (vasoactive abortive medications, acute opioids, and non-
steroidal anti-inﬂammatory drugs).
More importantly, another group of patients who raised intakes of
omega-3 nutrients in the presence of lowered intakes of competing
omega-6 nutrients lowered the %n-6 in HUFA from 77% to 61% in
3 months. These patients lowered their self-administration of acute
medications further as they reduced headache hours per day by 44%
[33]. This trial showed a clear beneﬁt in changing food intakes to
lower the HUFA balance below the level of 76–80%n-6 in HUFA that is
often observed for Americans. Shifting from 77% to 61%n-6 in HUFA
clearly has biological signiﬁcance.
A 2014 historical perspective of the impact of n-3 and n-6 nutrients
on health gave evidence for a very narrow therapeutic window for
dietary linoleic acid that is reﬂected by the health risk assessment
biomarker, the %n-6 in HUFA [34]. Fortunately, n-3 nutrients have no
known upper limit of risk [35], and their competitive actions widen
the therapeutic window for n-6 nutrients. Ramsden et al showed
clearly that dietary linoleate can cause harm [36] and that lowering
intakes of omega-6 nutrients while raising intakes of omega-3
nutrients [33] can be an effective form of preventive medicine. The
context of an unwanted diet-determined balance in tissue HUFA
which has an unwanted clinical outcome makes clear the need for
explicit public information about food choices by which people can
voluntarily balance their intakes of n-3 and n-6 nutrients and
maintain a tissue HUFA balance linked to lower risk of unwanted
health conditions.
Describing HUFA abundance in the context of competing
eicosanoid precursors may be regarded by some to introduce a
limiting bias. However, clinical reports that describe only wt%
amounts of n-3 EPA and DHA and omit data on the amounts of
competing n-6 HUFA fail to make accessible to the scientiﬁc
community important evidence related to the balance between
n-3 and n-6 HUFA that will be precursors of biologically signiﬁcant
eicosanoid actions. The competing n-3 and n-6 nutrients in each
food item give an Omega 3–6 Balance Food Score [37] that
summarizes data in the USDA Nutrient Database as a single value
expressing the balance among eleven omega-3 and omega-6
essential fatty acids in the food. As the average daily food balance
score for people with different food habits ranges from 8 to þ3,
the %n-6 in HUFA ranges from 88% to 28% [37]. Over 5000 different
Omega 3–6 Balance Scores are in an “app” for personal mobile
devices [38]. Using these food Scores along with semi-annual
monitoring of personal HUFA balance values from ﬁnger-tip blood-
spot assays gives a very simple corporate wellness intervention
that may decrease annual health care claim costs [24,34].
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Fig. 3. Three n-3 HUFA combined compete with arachidonate for accumulation in
tissue lipids and for subsequent downstream actions.
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